دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Equity in cancer drug access in the UK
doi : 10.1016/S1470-2045(22)00030-4
Volume 23, Issue 2, February 2022, Page 185
Promising outlook with sugemalimab in non-small-cell lung cancer
RafaelRosella†PengCaobcâ€
Targeting HER2 for localised oesophageal cancer
FlorianLordickaRadkaObermannovábElizabeth CSmythc
Is non-invasive Cytosponge the holy grail for Barrett's neoplasia?
MichaelViethaMarkus FNeurathbc
Overcoming immunotherapy resistance in NSCLC
MichaelMacManusabFionaHegi-Johnsonab
Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
HagaiLigumskyafHerutDorfTalEtanafInbalGolombafAllaNikolaevski-BerlinaInbalGreenbergfTamarHalperinbYoelAngelcfOryanHenigdfAvishaySpitzerafgMarinaSlobodkinefIdoWolfafCOVI3 study investigators
Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
GeorgPfeileraAngelaDeMichelecAmylou CDueckdChristianFesleMichaelGnantbErica LMayerf
Japan resumes active recommendations of HPV vaccine after 8·5 years of suspension
ReiHaruyamaaHiromiObaraaNorikoFujitaa
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform
Laurien JZeverijnacSahar Barjestehvan Waalwijk van Doorn-KhosrovanidAnke A M G Pistersvan RoydLonnekeTimmerseT HLy TraneJolanda Ede BoereGijsbrecht Fde WitacBirgit SGeurtsacHansGelderblomfHenk M WVerheulhNicoleBlijlevensiA N MachteldWymengajFerry A L MEskenskEgbert FSmitbgHaiko JBloemendalhEmile EVoestac
Global consequences of the US FDA's accelerated approval of cancer drugs
AmolAkhadeaBhawnaSirohibBishalGyawalic
Thank you to The Lancet Oncology's clinical and statistical peer reviewers in 2021
Nivolumab plus ipilimumab in melanoma brain metastases
AlessandroRizzo
Nivolumab plus ipilimumab in melanoma brain metastases
Anna MariaDi GiacomoabcMicheleMaioabc
Nivolumab plus ipilimumab in melanoma brain metastases – Authors' reply
Hussein ATawbiaZeynepEroglubCarey KAnderscKim AMargolind
Immune checkpoint inhibitors and timing of administration
TimothyO'BrienaLeonieDolanb
Immune checkpoint inhibitors and timing of administration
NazliDizmanaAna IVelazquezbNarjustDumac
Immune checkpoint inhibitors and timing of administration – Authors' reply
David CQianaZachary SBuchwalda
New EU regulation on health technology assessment of cancer medicines
Thomas JHwangaKerstin NVokingera
Omicron: NHS agrees 3-month deal with private sector to provide cancer care backup
EmmaWilkinson
An initiative to combat the cancer burden in Uruguay
ManjulikaDas
Should radiotherapy be considered for the initial treatment of brain metastases?
GiuseppeMinnitiEmilieLe Rhun
MSF breast and cervical cancer screening programmes in Mali and Malawi
SharmilaDevi
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
ProfQingZhouMDa†ProfMingChenMDbc†ProfOuJiangMDdProfYiPanMDaProfDeshengHuBMeQinLinPhDfProfGangWuMDgProfJiuweiCuiMDhProfJianhuaChangMDijProfYufengChengMDkProfChengHuangPhDlProfAnwenLiuMDmProfNongYangMScnProfYoulingGongMDoProfChuanZhuBMpProfZhiyongMaMMqProfJianFangMDrProfGongyanChenMDs…ProfYi-LongWuMDa
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
ProfCaicunZhouMDaProfZipingWangMDbProfYupingSunMDcdProfLejieCaoMMedeProfZhiyongMaMMedfProfRongWuMDgProfYanYuMDhProfWenxiuYaoMDiProfJianhuaChangMDjkProfJianhuaChenMMedlWuZhuangBMmProfJiuweiCuiMDnProfXueqinChenMMEdoProfYouLuMDpHongShenMDqJingruWangPhDrPeiqiLiMDrMengmengQinMMedr…JasonYangMDr
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
ProfYoon-KooKangMDaProfLi-TzongChenMDbcProfMin-HeeRyuMDaProfDo-YounOhMDdeSang CheulOhMDfProfHyun CheolChungMDgProfKeun-WookLeeMDhTakeshiOmoriMDiKoheiShitaraMDjProfShinichiSakuramotoMDkProfIk-JooChungMDlKenseiYamaguchiMDmKenKatoMDnProfSun JinSymMDoShigenoriKadowakiMDpKunihiroTsujiMDqJen-ShiChenMDrLi-YuanBaiMDs…NarikazuBokuMDn
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
ProfArlene OSiefker-RadtkeMDaProfAndreaNecchiMDbSe HoonParkMDcJesúsGarcÃa-DonasMDdRobert AHuddartPhDeEarle FBurgessMDfMark TFlemingMDgArashRezazadeh KalebastyMDhBegoñaMelladoMDiSergeiVarlamovMDjMonikaJoshiMDkIgnacioDuranMDlScott TTagawaMDmYousefZakhariaMDnSydneyAkapamePhDoAdemi ESantiago-WalkerPhDoManishMongaMDoAnneO'HaganMPHo…YousefZakharia
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
ProfHoward PSafranMDaKathrynWinterMScProfDavid HIlsonMDdProfDennisWigleMDgThomasDiPetrilloMDbProfMichael GHaddockMDhProfTheodore SHongMDiProfLawrence PLeichmanMDjLakshmiRajdevMDkProfMurrayResnickMDfProfLisa AKachnicMDlSamanthaSeawardMDmHarveyMamonMDnDayssy AlexandraDiaz PardoMDoCarryn MAndersonMDpXingleiShenMDqProfAnand KSharmaMDrAlan WKatzMDs…Christopher HCraneMDe
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot
Nastazja DagnyPilonisMDa†SarahKillcoynePhDa†W KeithTanMDaMariaO'DonovanMDabShaliniMalhotraMDabMonikaTripathiMDabAhmadMiremadiMDabIreneDebiram-BeechamRNaTaraEvansRNaRosemaryPhillipsMDcDanielle LMorrisMDdCraigVickeryMDeJonHarrisonMDfMassimilianodi PietroMDaJacoboOrtiz-Fernandez-SordoMDgRehanHaidryMDgAbigailKerridgeBScaProfPeter DSasieniPhDhProfRebecca CFitzgeraldMDa
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Jonathan DSchoenfeldMDabAnitaGiobbie-HurderMScSrinikaRanasinghePhDdKatrina ZKaoBAdAnaLakoPhDdJunkoTsujiPhDfYangLiuPhDcRyan CBrennickBSdRyan DGentzlerMDgCarrieLeeMDhJoleenHubbardMDiProfSusanne MArnoldMDjProfJames LAbbruzzeseMDkProfSalma KJabbourMDlNataliya VUbohaMDmKevin LStephansMDnJennifer MJohnsonMDoHaeseongParkMDp…ProfF StephenHodiMDdeâ€
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
ProfDavidCellaPhDa†ProfRobert JMotzerMDb†CristinaSuarezMDcSteven IBlumMAdFlaviaEjzykowiczPhDdMelissaHamiltonMPHdJoel FWallacePharmDeBurcinSimsekPhDdJoshuaZhangMDdCristinaIvanescuPhDfAndrea BApoloMDgProfToni KChoueiriMDh
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
Amar UKishanMDab*YilunSunPhDfg*HollyHartmanPhDfgProfThomas MPisanskyMDhProfMichelBollaMDiAnoukNevenMScjAllisonSteiglerBMathkProfJames WDenhamFRANZCRkProfFelix YFengMDlAlmudenaZapateroMD PhDmProfJohn GArmstrongMDnAbdenourNabidMDoNathalieCarrierMScpProfLuisSouhamiMDqMary TDunneMScnProfJason AEfstathiouMDrProfHoward MSandlerMDsAraceliGuerreroMDt…ProfDaniel ESprattMDg
Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities
Diana DShiMDa*Jimmy AGuoBAbcdef*Hannah IHoffmanBAbdhiJenniferSuBSbdhProfMariMino-KenudsonMDjJaimie LBarthBSjJason MSchenkelMDhkProfJay SLoefflerMDbProfHelen AShihMDbProfTheodore SHongMDbJennifer YWoMDbAndrew JAguirreMDfProfTylerJacksPhDhProfLeiZhengMDlProfPatrick YWenMDgProfTimothy CWangMDmWilliam LHwangMDbdh
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
CourtneyLawhn-HeathMDaThomas AHopeMDabeJuanaMartinezMDfEdward KFungPhDfJaehoonShinMDaProfYounghoSeoPhDabcgRobert RFlavellMDabd
Bone marrow invasion in breast carcinoma
AnneliesFeyaertsMDaWimDemeyMDb
